Skip to main content

Table 6 Adverse events in patients treated as adjuvant/first-line setting (n = 32)

From: Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients

Adverse event

G0

G1

G2

G3

G4

NE

All grades (%)

Grade 3/4 (%)

Leucocyte

3

3

8

10

7

1

87.5

53.1

Neutrophils

2

3

5

8

13

1

90.6

65.6

Hemoglobin

10

8

8

5

0

1

65.6

15.6

Platelets

19

3

6

3

0

1

37.5

9.4

AST

22

6

2

1

0

1

28.1

3.1

ALT

22

5

1

3

0

1

28.1

9.4

Anorexia

13

14

5

0

0

0

59.4

0.0

Nausea

17

11

4

0

0

0

46.9

0.0

Vomiting

26

5

1

0

0

0

18.8

0.0

Diarrhea

26

4

1

1

0

0

18.8

3.1

Fatigue

14

12

5

1

0

0

56.3

3.1

Febrile neutropenia

29

0

0

3

0

0

9.4

9.4

Fever

24

6

1

1

0

0

25.0

3.1

Infection

29

0

1

2

0

0

9.4

6.3

Dyspnea

31

0

0

1

0

0

3.1

3.1

Interstitial pneumonia

30

2

0

0

0

0

6.3

0.0

Neuropathy

32

0

0

0

0

0

0.0

0.0

Rash

24

4

3

1

0

0

25.0

3.1

Edema

30

2

0

0

0

0

6.3

0.0

Mucositis

31

0

1

0

0

0

3.1

0.0

Allergic reaction

32

0

0

0

0

0

0.0

0.0

  1. AST aspartate transaminase, ALT alanine aminotransferase